BioNexus Gene Lab Corp. (BGLC) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 812.94K USD | Liabilities, Current |
| Cash and equivalents | 1.23M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 15.54K USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 652.89K USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $812.94K | $1.23M | (m) | $15.54K | $652.89K | (m) |
| 2026-03-31 | (m) | $796.47K | (m) | (m) | $79.86K | $667.15K | (m) |
| 2025-12-31 | (m) | $520.96K | $2.49M | (m) | $505.88K | $676.70K | (m) |
| 2025-09-30 | (m) | $678.02K | (m) | (m) | $1.52M | $1.01M | (m) |
| 2025-06-30 | (m) | $1.76M | (m) | (m) | $1.85M | $1.22M | (m) |
| 2025-03-31 | (m) | $1.56M | (m) | (m) | (m) | $1.18M | (m) |
| 2024-12-31 | (m) | $1.95M | (m) | (m) | (m) | $1.39M | (m) |
| 2024-09-30 | (m) | $1.41M | (m) | (m) | (m) | $1.39M | (m) |
| 2024-06-30 | (m) | $1.40M | (m) | (m) | (m) | $1.03M | (m) |
| 2024-03-31 | (m) | $1.72M | (m) | (m) | (m) | $1.08M | (m) |
| 2023-12-31 | (m) | $1.63M | (m) | (m) | (m) | $1.14M | (m) |
| 2023-09-30 | (m) | $1.64M | (m) | (m) | (m) | $1.11M | (m) |
| 2023-06-30 | (m) | $1.88M | (m) | (m) | (m) | $1.17M | (m) |
| 2023-03-31 | (m) | $1.56M | (m) | (m) | (m) | $899.64K | (m) |
| 2022-12-31 | (m) | $2.00M | (m) | (m) | (m) | $977.81K | (m) |
| 2022-09-30 | (m) | $1.33M | (m) | (m) | (m) | $1.10M | (m) |
| 2022-06-30 | (m) | $1.50M | (m) | (m) | (m) | $1.51M | (m) |
| 2022-03-31 | (m) | $1.98M | $1.84M | (m) | (m) | $1.65M | (m) |
| 2021-12-31 | (m) | $2.33M | $2.12M | (m) | (m) | $1.52M | (m) |
| 2021-09-30 | (m) | $2.66M | $1.70M | (m) | (m) | $1.49M | (m) |
| 2021-06-30 | (m) | $2.58M | $1.48M | (m) | (m) | $1.70M | (m) |
| 2021-03-31 | (m) | $3.04M | $2.47M | (m) | (m) | $1.47M | (m) |
| 2020-12-31 | (m) | $3.37M | $2.79M | (m) | (m) | $1.18M | (m) |
| 2020-09-30 | (m) | $38.16K | $264.52K | (m) | (m) | $19.16K | (m) |
| 2020-06-30 | (m) | $46.45K | $728.49K | (m) | (m) | $21.10K | (m) |
| 2020-03-31 | (m) | $47.35K | (m) | (m) | (m) | $7.21K | (m) |
| 2019-12-31 | (m) | $51.57K | (m) | (m) | (m) | $7.58K | (m) |
| 2019-09-30 | (m) | $27.10K | $977.15K | (m) | (m) | $11.82K | (m) |
| 2019-06-30 | (m) | $64.17K | (m) | (m) | (m) | $5.94K | (m) |
| 2019-03-31 | (m) | $66.18K | (m) | (m) | (m) | $10.05K | (m) |
| 2018-12-31 | (m) | $62.89K | $1.26M | (m) | (m) | $15.30K | (m) |
| 2018-09-30 | (m) | (m) | $1.42M | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | $839.14K | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |